The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective comparison of uPA/PAI-1 and EndoPredict-clin score in ER-positive, HER2-negative breast cancer: Impact on risk stratification and treatment decisions.
Johannes Ettl
No relevant relationships to disclose
Kirsten Grosse Lackmann
No relevant relationships to disclose
Alexander Hapfelmeier
No relevant relationships to disclose
Evelyn Klein
No relevant relationships to disclose
Stefan Paepke
No relevant relationships to disclose
Christoph Petry
Employment or Leadership Position - Sividon Diagnostics
Stock Ownership - Sividon Diagnostics
Katja Specht
No relevant relationships to disclose
Heinz Hoefler
No relevant relationships to disclose
Marion Kiechle
Honoraria - Sividon Diagnostics
Research Funding - Sividon Diagnostics